Advisor Group Holdings, Inc. Savara Inc Transaction History

Advisor Group Holdings, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$3.66 - $5.34 $2,228 - $3,252	609 Added 304.5%	809 $3,000
Q1 2024 May 10, 2024	SELL	$4.19 - $5.59 $117 - $156	-28 Reduced 12.28%	200 $0
Q2 2023 Aug 21, 2023	SELL	$1.69 - $3.24 $103 - $197	-61 Reduced 21.11%	228 $0
Q2 2023 Aug 10, 2023	BUY	$1.69 - $3.24 $150 - $288	89 Added 44.5%	289 $0
Q1 2023 May 12, 2023	BUY	$1.6 - $2.82 $320 - $564	200 New	200 $0
Q3 2021 Nov 05, 2021	SELL	$1.18 - $1.64 $11,800 - $16,400	-10,000 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$1.0 - $1.47 $10,000 - $14,700	10,000 New	10,000 $12,000
Q2 2020 Aug 14, 2020	SELL	$1.8 - $3.05 $10 - $18	-6 Closed	0 $0
Q1 2020 May 18, 2020	BUY	$1.91 - $4.08 $11 - $24	6 New	6 $0

129

151M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $328M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.